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Objective: Prior studies suggested that early drain removal prevented the development of pancreatic 
fistula (PF) after pancreaticoduodenectomy (PD), but there has been no corresponding prospective trial 
for distal pancreatectomy (DP). The purpose of this study was to determine the safety and efficacy of 
early drain removal and triple-drug therapy (TDT) with gabexate mesilate, octreotide and carbapenem 
antibiotics to prevent PF after DP in patients at high-risk of developing PF. 
Methods: A total 71 patients who underwent a DP were enrolled. We prospectively divided them into 
two groups: the late-removal group, in which the drain remained in place for at least for 5 days 
postoperatively (n=30) and the early-removal group in which the drain was removed on postoperative 
day1 (POD1) (n=41). For the patients with a high drain amylase level (≥ 10,000 IU/L) and patients with 
symptomatic intraperitoneal fluid collection, our original TDT was introduced. The primary endpoint 
was the safety and efficacy of this management, and the secondary endpoint was the incidence of PF. 
Results: The incidence of clinical PF was significantly lower in the early-removal group (0% vs. the 
late removal 16%; p<0.001). In the early-removal group, TDT was administered to 12 patients (29%) 
and none of the patients needed additional treatment after TDT. 
Conclusions: Postoperative management after DP with early drain removal and TDT was safe and 
effective for preventing PF. 




Distal pancreatectomy (DP) is generally performed for benign and malignant tumors of the left side of 
the pancreas. Several operative procedures for these tumors have been developed over the past 20 
years, including the use of spleen preservation (1) and laparoscopic surgery (2). However, the 
incidence of the most common and most serious postoperative complication after DP, postoperative 
pancreatic fistula (PF), was not found to be improved in several clinical prospective trials (3–5). It is 
apparent that a radical change in postoperative management is necessary to prevent PF after DP. 
Kawai et al. (6) reported the efficacy of early drain removal to prevent PF after 
pancreaticoduodenectomy (PD) for pancreas-head disease, and Bassi et al. (7) followed the early drain 
removal method and obtained the same results. Kawai et al. speculated that the reason for these 
favorable results is that there is a close association between infection via an inserted drain and 
subsequent PF development, and long-term drain insertion might cause intraperitoneal infections, 
including PF (6). In light of these results, it seems that prophylactic long-term drain insertion after PD 
is not ideal, and that it may be possible to prevent PF by early drain removal. However, to the best of 
our knowledge, prospective trials of early drain removal to prevent PF have not been conducted. The 
present prospective study was conducted to clarify whether PF after DP can be prevented by early 
drain removal. 
Two groups reported that the incidence rate of PF after DP was higher than that after PD (8,9). 
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This finding implies that early drain removal could also be the cause of an increase of intraperitoneal 
abscess or intraperitoneal bleeding due to the rupture of a pseudoaneurysm. To reduce such an 
assumptive risk in the present study, we introduced an original triple-drug therapy (TDT) for high-risk 
patients whose drainage fluid had a high amylase level (i.e., a high drain amylase level) on 
postoperative day 1 (POD1) or any unusual symptom associated with intraperitoneal fluid collection 
after drain removal. The purpose of this study was to determine the safety and efficacy of the early 
drain removal and TDT to prevent PF after DP in high-risk PF patients. 
 
PATIENTS AND METHODS 
Patients 
This was a prospective study conducted at the Department of Surgery, Nagasaki University Hospital. 
The study design and protocol were approved by the Institutional Review Board at our hospital. From 
June 2005 to April 2013, 79 DP procedures were performed in our department, and we divided the 
patients into two groups according to the day of drain removal as follows: the late-removal group, who 
underwent a DP in the period from June 2005 to September 2009, during which the drains were inserted 
for at least postoperative 5 days, and the early-removal group, who underwent a DP in the period from 
October 2009 to April 2013, during which the drain in all cases was removed on POD1 (Fig 1). 
Of the 33 patients in the late-removal group, three patients were excluded from the present study 
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due to the combined resection of the remnant pancreas (one patient each because of pancreas head 
resection with a second portion of duodenectomy, duodenum-preserving pancreas head resection, and 
uncinectomy). Of the 46 patients in the early-removal group, five patients were excluded: combined 
with other-organ resection (one patient each for the colon and left kidney), one patient with uncinectomy 
of the remnant pancreas, and two patients because of postoperative intraperitoneal bleeding via the drain 
on the day of surgery. Thus a total of 30 patients in the late-removal group and 41 patients in the early-
removal group were enrolled. 
 
Operative procedure 
Different types of DP procedures were performed in the study period. Spleen preservation and 
laparoscopic surgery were often performed for the low-grade malignant tumors such as intraductal 
papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN). For invasive ductal 
carcinoma, DP by means of laparotomy with splenectomy and lymph node dissection was always 
performed. For the pancreas stump closure, approx. one-half of the cases were transected by stapler 
(Endo GIA™ 60-mm Articulating Medium/Thick Reload with Tri-Staple™ Technology, Covidien, 
Mansfield, MA, USA) and the other half were closed by the fish mouse technique or gastric wall 
covering (10). A closed suction drain was always placed near the pancreas stump and pulled out from 
the patient’s left-side abdominal wall. 





On the day of surgery, all patients were controlled in the intensive-care unit and then moved to the 
general ward on POD1. Prophylactic antibiotics therapy by using the cefem was administered for three 
days including the day of surgery as a standard clinical practice. No other medicine which had the 
possibility to prevent PF was administered. 
The drain amylase level was measured on POD1, 3, and 5 in the late-removal group, and on only 
POD1 in the early-removal group. In the late-removal group, the drain was removed unless clearly 
purulent fluid was drained on POD5, regardless of the drain amylase level or the amount of output. If 
purulent fluid was drained before POD5, drainage management was continued until the purulent output 
disappeared. In the early-removal group, the drain was always removed on POD1, regardless of the 
drain amylase level or amount of output. 
TDT with gabexate mesilate (600 mg/day as a continuous intravenous injection [c.i.v.]), 
octreotide (300 µg/day c.i.v.) and antibiotic; carbapenem (0.5 g/day intravenous injection [i.v.]) 
antibiotics was administered to late-removal group patients with a high drain amylase level (≥ 10,000 
IU/L) on POD1, 3, or 5 and to early-removal group patients with a high drain amylase level (≥ 10,000 
IU/L) on POD1, and to patients who had developed any clinical symptoms (e.g., a fever ≥ 38°C, 
abdominal pain or fullness) with the intraperitoneal fluid collection after drain removal. According to 
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the antibiotic, carbapenem was employed for this study based on the results of the bacterial sensitivity 
of the drain tip culture after PD in our department (data not shown). Intraperitoneal fluid collection was 
confirmed by enhanced computed tomography (CT) or ultrasound (US). After the disappearance of 
clinical symptoms and a tendency for the patient’s serum C-reactive protein (CRP) to decrease were 
confirmed, the patient’s diet was restarted and the components of the TDT were discontinued one by 
one (Fig.2). If the patient’s condition was not improved by the TDT, additional treatment such as drain 
re-insertion or relaparotomy was performed. 
 
Date analysis and definition 
As clinicopathologic variables for the evaluation in the present study, the following perioperative factors 
were recorded for each patient: age, gender, tumor characteristics, diabetes mellitus, preoperative white 
blood cells (WBC count), lymph cells (count and %), the serum levels of total protein, albumin, and 
amylase; pancreas texture, which was confirmed mainly by the time-intensity curve of magnetic 
resonance imaging (MRI) (11), operative procedure (laparotomy, hand-assisted, or pure laparoscopy), 
the presence of lymph node dissection and spleen preservation, the method of pancreas stump closure, 
the operative time, blood loss, the presence of blood transfusion, postoperative WBC (count), serum 
CRP and amylase on POD1, 3, and 7. The date of drain amylase level evaluation was described above. 
We defined PF according to the criteria established by the International Study Group on 
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Pancreatic Fistula (ISGPF) (12), and grade B/C was considered PF in the present study; specifically, 
intraperitoneal drain re-insertion or over 20 days of drainage was considered PF grade B, and 
relaparotomy was considered PF grade C. Readmission was defined as admission due to a postoperative 
complication during the 3 months after the patient’s initial discharge. 
 
Study end points  
The study’s primary endpoints were the safety and efficacy of the present management (early drain 
removal and TDT for patients at high risk PF development), including indications of the necessity of 
additional invasive treatment. The secondary endpoint was the incidence of PF. We also performed a 
statistical analysis to detect risk factors of PF development. 
 
Statistical analyses 
Variables are described as either absolute numbers or median values and ranges. The Mann-Whitney U-
test and Fisher’s test were used for the comparative evaluation between the two patient groups. 
Quantitative variables were divided into two categories by the median value in the present multivariate 
analysis. P-values <0.05 were considered significant. 
 
RESULTS 
The clinical characteristics of the enrolled patients in both groups are summarized in Table 1. The serum 
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total protein level was significantly lower in the late-removal group (6.6 vs. 7.2 mg/dL, p=0.02), and 
both the operative procedure and the pancreas stump closure method (pancreas transection procedure) 
differed significantly between the two groups. The rates of blood loss and transfusion were significantly 
lower in the early-removal group. 
Regarding the postoperative outcomes (Table 2), the drain amylase levels were not significantly 
different between the late- and early-removal groups (2,284 vs. 921 IU/L, p=0.15). Although TDT was 
introduced for 24% of the late-removal group, similarly to the early-removal group (29%, p=0.64), PF 
development was completely prevented in the early-removal group (0%), unlike the late-removal group 
(16%) (p<0.001). Understandably, the duration of the drain insertion differed between the groups (late 
removal, 5 days vs. early removal, 1 day, p<0.001), the duration of hospital stay was essentially the 
same (late, 17 days vs. early, 16.5 days). 
From the every variables described in table 1 and 2, identified variables as the predictive factors 
for the development of PF by the univariate analysis are shown in Table 3. Although we divided the 
quantitative variables into two categories by the median value, each value of the patients with PF was 
so biased coincidentally that none of the predictive factors of PF were identified by the multivariate 
analysis. Therefore, based on the results of the univariate analysis, some variables — especially pancreas 
transection without a stapler and late removal of the drain— would strongly increase the risk of the 
development of PF after DP. 
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The cases of the patients who required additional treatment are summarized in Table 4. As shown, 
although five patients in the late-removal group received invasive additional treatment (one 
relaparotomy and four drain management), none of the patients in the early-removal group required any 
additional or invasive treatment. Eighteen patients in all were treated only with the TDT, and none of 
these 18 patients underwent additional treatment such as percutaneous drainage or relaparotomy. 
Moreover, all of the symptoms (i.e., fever up or abdominal fullness) which caused the introduction of 
the infusion therapy in patients in the early-removal group disappeared within 3 days after the 
introduction of TDT. As a result, there were no patients in the early-removal group who had to prolong 
the TDT over the protocol setting. There were no mortality in either group during the study period, but 
readmission was required for one of the patient in each group for varying reasons during the 3 months 
after their initial discharge. 
 
DISCUSSION 
In the present study, PF development after DP was prevented by means of early drain removal and TDT, 
especially for high-risk patients whose drain amylase level was high or who developed abdominal 
symptoms. Early drain removal was shown earlier to be effective to prevent PF after PD (7), and high 
drain amylase level (≥ 4,000 IU/L) on POD1 was reported to be an independent prognostic factor for PF 
development (13). At our hospital, therefore, intensive TDT was introduced for the patients with high 
drain amylase levels since they had a potentially high risk of PF development and for patients showing 
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clinical symptoms that may be an early sign of PF development after early drain removal. In other words, 
the prevention of PF in the present patient population was achieved by the combination of these two 
strategies, early drain removal and TDT. 
In regard to early drain removal after DP, it should be emphasized that early drain removal (i.e., 
on POD1) and initial no drain management — which has been reported after PD (14,15) and after PD/DP 
(16,17) — are intrinsically different protocols for safe postoperative management. We have found that 
the operative drain is useful as both an informative tool for intraperitoneal bleeding immediately after 
surgery, and to identify patients at high risk of PF development by the evaluation of the drain amylase 
level. In the present study, we had two cases of intraperitoneal bleeding immediately after surgery (these 
cases were excluded from this study), and the patients were safety treated because of the early detection 
of bloody drainage via the drain, Moreover, we suspect that the evaluation of the drain amylase level on 
POD1 itself can contribute to the prevention of PF. 
As a cut-off value for the drain amylase level for the introduction of TDT, we used 10,000 IU/L 
in the present study. This value was determined based on the median drain amylase level on POD1 in 
the patients with PF development after PD in our hospital (data not shown). The drain amylase levels of 
4,000 IU/L on POD1 with PD (13) and 5,000 IU/L on POD1 after PD or DP (18) were described as the 
cut-off value for the independent risk factor of PF development. The median drain amylase level on 
POD1 in the present study’s patients who were eventually administered the TDT was not so high, approx. 
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3,000 IU/L, and thus the present 10,000 IU/L drain amylase cut-off seems to present a more risky 
disadvantage. However, in our early-removal group, no patients developed PF or suffered from a 
prolonged abdominal symptom due to intraperitoneal fluid collection. We therefore feel that 10,000 
IU/L of drain amylase level is suitable as the cut-off value for the introduction of TDT. 
Three types of medicine which are thought to help prevent PF were used simultaneously as the 
TDT in the present patient series. There have been no articles describing results of this combination 
therapy, but reports of the efficacy of each medicine to prevent PF after PD have been published. For 
example, concerning a proteolytic enzyme inhibitor that corresponds to the gabexate mesilate used in 
the present study, Uemura et al. described the efficacy of ulinastatin for preventing PF (19). There are 
more papers about octreotide, including some reviews describing negative conclusions (20–22). In the 
present study, three types of medicine were used simultaneously to make the treatment as effective as 
possible, the administration method of octreotide was changed (continuous venous injection, not 
subcutaneous injection), and the introduction of TDT was restricted to patients at high risk of PF 
development. These aspects of the TDT protocol were expected to lead to the successful and significant 
prevention of PF. However, further evaluations concerning the dose and duration of the TDT and the 
possibility of omitting one or more of the three drugs are needed. 
It seems difficult to assess the precise time when fluid collection developed in the early-removal 
group, but an important finding of our study was that the intraperitoneal fluid collection with any 
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symptom could be controlled by the TDT without drainage management, even if it developed 
immediately after surgery or a few days later. We therefore recommend early drain removal and TDT, 
especially for symptomatic patients with intraperitoneal fluid collection after DP. However, the efficacy 
of this treatment protocol for patients with severe abdominal symptoms or massive fluid collection could 
not be evaluated in the present study. Careful observation of the patient during this TDT regimen and 
possible need for drainage or relaparotomy when a patient’s status worsens are important. 
We were not able to conduct a statistical examination of bacterial cultures using drainage fluid or 
an inserted drain tip because a culture examination was performed in only some of the patients. Positive 
culture findings and the development of PF were reported to be closely related (6,23), and early drain 
removal is thought to have contributed to the prevention of retrograde infection via the drain. 
Interestingly, among the 19 patients in the present early-removal group whose drain tip was evaluated 
by a bacterial culture examination, all three patients with positive findings eventually required the TDT 
after drain removal. We consider this an important result indicating the significance of the control of 
intraperitoneal infection (or colonization) to prevent PF, and we propose that further evaluations 
regarding infection prevention in the peritoneal cavity during the intraoperative period should be 
performed to prevent PF, even if the drain is removed on POD1. 
A qualitative problem in the present study should be mentioned. In the group setting of this 
study, some clinical aspects of the patients such as pancreas transection procedure, blood loss or blood 
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transfusion were different between two groups. This is why the group setting was decided by the era in 
the study period. We should conduct the randomized controlled trial to clarify the efficacy of the early 
drain removal and TDT for preventing PF after DP. 
In conclusion, we found that postoperative management after DP with early drain removal and 
TDT was safe and effectively prevented PF, and no invasive treatments were required in the early-
removal group. However, randomized controlled trials of larger numbers of patients should be 
performed to obtain more precise data for the evaluation of early drain removal and TDT. 
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Fig. 1. Patients flow of this study. PHRSD: Pancreas head resection with segmental duodenectomy, 
DPPHR: Duodenum preserved pancreas head resection.  
 
Fig. 2. TDT for high drain amylase levels (over 10,000 IU/L) in the early-removal group. TDT was 
introduced from POD1, and after confirmation of the absence of any clinical unusual symptom and the 
decrease of the patient’s serum CRP level after POD7, the TDT components were omitted one by one. 





Table 1. Preoperative and operative characteristics of the patients
Variable late removal (n=30) early removal (n=41) p
gender (male/ female) 13/17 24/17 0.58
age (years) 67.5 (35–82) 64.0 (30–86) 0.20
invasive malignant tumor (%) 11/30 (37%) 11/41 (27%) 0.38
diabetes mellitus (%) 12/30 (40%) 8/41 (19%) 0.06









) 1.6 (0.4–3.8) 1.5 (0.5–3.1) 0.40
lymph cells (%) 0.35 (0.05–0.65) 0.27(0.07–0.53) 0.05
total protein (g/dL) 6.6 (5.5–7.9) 7.2 (5.7–8.0) 0.02
albumin (g/dL) 4.1 (2.5–5.0) 4.1 (2.2–4.9) 0.13
amylase (g/dL) 73 (21–238) 62 (8–243) 0.25
soft pancreas (%) 22/30 (73%) 36/41 (88%) 0.28
operative procedure (laparotomy/ HALS/ pure-LAP) 12/17/1 11/15/15 0.004
lymph node dissection (%) 13/30 (43%) 14/41 (34%) 0.43
spleen preservation (%) 8/30 (27%) 16/41 (39%) 0.28
pancreas transection by stapler 4/30 (13%) 34/41 (83%) ˂ 0.0001
operative time (min) 383 (168–623) 335 (148–578) 0.15
blood loss (mL) 790 (60–3400) 260 (5–3000) 0.007
blood transfusion (%) 11/30 (37%) 4/41 (10%) 0.006
HALS: hand-assisted laparoscopic surgery, LAP: laparoscopic surgery
Table 2. Comparison of the postoperative outcomes
Variable late removal (n=30) early removal (n=41) p




) 12.4 (7.400–18.9) 11.5 (4.0–24.1) 0.84
          　            POD7 6.7 (3.8–13.2) 7.0 (2.8–13.2) 0.50
CRP  POD1 (mg/dL) 10.0 (2.7–25.7) 9.1 (3.1–18.0) 0.03
         POD7 3.6 (0.4–24.9) 5.0 (0.6–13.6) 0.11
amylase  POD1 (g/dL) 132 (18–1795) 98 (12–204) 0.003
　　　　    POD7 61 (12–213) 33 (7–110) 0.003
drain amylase level (IU/L) POD1 2284 (17–42570) 921 (112–87550) 0.15
                        　             POD3 876 (10–13626) n/a –
                                        POD5 367 (7–6043) n/a –
TDT: triple-drug therapy (%) 6/25 (24%) 12/41 (29%) 0.64
PF: pancreas fistula(%) 5/30 (16%) 0/41 (0%) ˂ 0.001
duration of drain insertion (days) 5 (5–60) 1 (1–1) ˂ 0.001
Clavien-Dindo grade III a PF: 4, cyle leak:1 0
                               III b PF: 1 0
                                     IV a pneumoniae: 1 ARDS: 1
                                     IV b/ V 0 0
hospital stay (days) 17.5 (9–116) 16.0 (5–41) 0.25
readmission during 3 months after discharge (%) 1/30 (3%) 2/41 (5%) 0.75
0.006
n/a.: not applicable, ARDS: Acute respiratory distress symdrome
Table 3. Univariate analysis for predictive factors of PF
Variable PF (−) (n=66) PF (+) (n=5) p
blood loss (mL) ˂416 (n=35) 35 0
416 ≤ (n=36) 31 5 (14%)
lymph node dissection no (n=44) 43 1 (2%)
yes (n=27) 23 4 (15%)
pancreas transection by stapler no (n=33) 28 5 (15%)
yes (n=38) 38 0




) ˂9.3 (n=33) 33 0
9.3 ≤ (n=38) 33 5(13%)
CRP POD1 (mg/dL) ˂9.54 (n=35) 35 0
9.54 ≤ (n=36) 31 5(14%)
amylase POD1 (IU/L) ˂105 (n=35) 35 0
105 ≤ (n=36) 31 5(14%)
drain amylase level POD1 (IU/L) ˂1254 (n=34) 34 0
1254 ≤ (n=37) 32 5(14%)
drain late removal (n=30) 25 5(17%)
early removal (n=41) 41 0
duration of drain insertion (days) 1 (1–60) 1 (1–5) 20 (5–60) ˂ 0.001









Table 4. Summary of the causes of additional treatment in each patient
Additional treatments late-removal group (11/30: 37%) early-removal group (12/41: 29%)
relaparotomy after drainage and TDT duodenum perforation due to PF on POD90
long-term drain insertion with TDT drain removed on POD20
drain removed on POD28
drain re-insertion after TDT initial drain removed on POD5, re-insertion from POD9 to 20
initial drain removed on POD12, re-insertion from POD16 to 60
TDT only intraperitoneal fluid collection with fever up (POD 2) intraperitoneal  fluid collection with fever up (POD 2)
intraperitoneal fluid collection with fever up (POD 6) intraperitoneal  fluid collection with fever up (POD 2)
intraperitoneal fluid collection with fever up (POD 8) intraperitoneal  fluid collection with fever up (POD 3)
intraperitoneal  fluid collection with abdominal fullness (POD 6) intraperitoneal  fluid collection with fever up (POD 4)
high drain amylase level (12605 IU/L) (POD 1) intraperitoneal  fluid collection with fever up (POD 5)
high drain amylase level (13626 IU/L) (POD 3) intraperitoneal  fluid collection with fever up (POD 5)
intraperitoneal  fluid collection with fever up (POD 6)
intraperitoneal  fluid collection with fever up (POD 8)
intraperitoneal  fluid collection with fever up (POD 9)
high drain amylase level (10639 IU/L) (POD1)
high drain amylase level (35628 IU/L) (POD1)
high drain amylase level (87550 IU/L) (POD1)
hospital stay (days) 23.5 (19–74) 23.5 (15–41)
readmission unruptured pseudo aneurysm of splenic artery (1 day after discharge) pseudocyst of the remnant pancreas (30 days after discharge) 
TDT: triple drug therapy
